Cargando…
Treatment of mucocutaneous manifestations in Behçet’s disease with anakinra: a pilot open-label study
BACKGROUND: The effect of IL-1 blocking therapy on mucocutaneous manifestations of Behçet’s disease is incompletely understood. METHODS: Six patients with Behçet’s disease and ongoing oral/genital ulcers for ≥1 month were enrolled into an adaptive, two-phase clinical trial and included in the analys...
Autores principales: | Grayson, Peter C., Yazici, Yusuf, Merideth, Melissa, Sen, H. Nida, Davis, Michael, Novakovich, Elaine, Joyal, Elizabeth, Goldbach-Mansky, Raphaela, Sibley, Cailin H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364674/ https://www.ncbi.nlm.nih.gov/pubmed/28335798 http://dx.doi.org/10.1186/s13075-017-1222-3 |
Ejemplares similares
-
Clinical, Endoscopic, and Histopathologic Gastrointestinal Disease in an American Cohort With Behçet's Disease
por: Curtin, Bryan F., et al.
Publicado: (2023) -
Mucocutaneous Manifestations of Behçet's Disease
por: Nakamura, Koichiro, et al.
Publicado: (2021) -
Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes
por: Kullenberg, Torbjörn, et al.
Publicado: (2016) -
Mucocutaneous manifestations of Behçet’s disease: Pathogenesis and management from perspectives of vasculitis
por: Kim, Doyoung, et al.
Publicado: (2022) -
Mucocutaneous Lesions of Behçet's Disease
por: Alpsoy, Erkan, et al.
Publicado: (2007)